Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyRăzvan Cristescu, David R. Kaufman, Robin Mogg et al.|Science|2018Cited by 2.3k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Daniel Castellano et al.|The Lancet Oncology|2017Cited by 1.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Manish Kohli et al.|Journal of Clinical Oncology|2018Cited by 1.1k
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial CancerJacqueline Vuky, Elizabeth R. Plimack, Arjun Vasant Balar et al.|Journal of Clinical Oncology|2020Cited by 292
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw Twardowski, Primo N. Lara, Catherine M. Tangen et al.|Kidney Cancer|2017Cited by 41